RxDoctor Payments Data

Nan Jiang, MD

Neurology · Birmingham, ALNPI 1316207244

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (41.5%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by AstraZeneca at 42.7% of the total. Reporting peaked in 2019 at $9,414 and has fallen 88.6% since, to $1,078 in 2025.

$29,508in general payments, 2019–2025

Across 79 payments — averaging $373.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$13K
  • CSL Behring$7K
  • Argenx US, Inc.$3K
  • Amylyx Pharmaceuticals, Inc.$2K
  • Akcea Therapeutics, Inc.$2K
  • Janssen Scientific Affairs, LLC$2K
  • plus $1K from 7 others
$24,313in research payments, 2019–2025

Across 5 payments — averaging $4862.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$24K

What the payments were for

  • Consulting fees$12,25842%
  • Speaking & faculty fees$10,88237%
  • Travel & lodging$2,5299%
  • Food & beverage$3,69213%
  • Education$1481%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,508 in reported general payments places this provider in the 80th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$33,989
Medicare patients
132
Services billed
446

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone70$1,006,197
PanzygaImmun Glob G(Igg)-Ifas/Glycine18$569,993
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5026$519,152
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5044$413,638
TeglutikRiluzole20$76,493
Gamunex-CImmune Globul G/Gly/Iga Avg 4611$49,400
Riluzole55$24,304
Pyridostigmine Bromide ErPyridostigmine Bromide13$8,472
Mycophenolate Mofetil36$5,221
Pyridostigmine Bromide65$4,412
Azathioprine28$1,930
Glycopyrrolate43$1,618
Prednisone102$781
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen13$576
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen19$449

Paid to pharmacies, not to this prescriber.

Other neurology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →